Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
- Conditions
- Advanced Nonsmall Cell Lung Cancer
- Registration Number
- NCT00602433
- Lead Sponsor
- Northwestern University
- Brief Summary
Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels.
This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.
- Detailed Description
Patients undergo a dermatology evaluation and complete the Polycystic Ovarian Syndrome (PCOS) research study questionnaire once. Blood samples are collected after an overnight fast. Samples are analyzed for circulating levels of total and bioavailable testosterone, dehydroepiandrosterone sulfate, and sex hormone binding globulin. Serum luteinizing hormone, follicle stimulating hormone, fasting glucose, and insulin levels are also assessed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 10
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence of hyperandrogenemia One approximate 30 minute visit We will determine if hyperandrogenemia is present in women with nonsmall cell lung cancer who are taking erlotinib.
- Secondary Outcome Measures
Name Time Method Changes in body habitus and patterns of hair loss One approximate 30 minute visit We will describe changes in body habitus and patterns of hair loss from women on erlotinib.
Dermatologic manifestations One approximate 30 minute visit We will describe the dermatologic manifestations of erlotinib in women
Trial Locations
- Locations (1)
Northwestern University, Northwestern Medical Faculty Foundation
🇺🇸Chicago, Illinois, United States